

Get the latest on Aplenzin XR availability in 2026. Is there a shortage? What's causing it? Here's what patients need to know right now.
If you're struggling to find Aplenzin XR at your pharmacy, you're probably wondering: is there an actual shortage? The answer is nuanced — and understanding it can help you get your prescription filled faster.
As of March 2026, Aplenzin (Bupropion Hydrobromide) is not officially listed on the FDA's drug shortage database. But that doesn't mean it's easy to find. Aplenzin is a brand-only medication manufactured by a single company (Bausch Health), and many pharmacies across the country simply don't stock it. The result feels like a shortage even if the supply chain says otherwise.
Yes. Patients across the U.S. continue to report difficulty finding Aplenzin XR at local pharmacies in 2026. Here's why the situation persists:
For a deeper dive into the supply dynamics, read our post on why Aplenzin XR is so hard to find in 2026.
Understanding the root causes helps you plan better.
The broader Bupropion market has been rocky. Generic Bupropion HCl extended-release products experienced significant shortages in 2023 and 2024 due to manufacturing disruptions and surging demand. While the generic supply has improved, some patients who struggled during those shortages moved to Aplenzin — putting pressure on an already limited supply.
Although generic Bupropion HCl (Wellbutrin XL equivalent) has been available for years, no generic version of Aplenzin (Bupropion Hydrobromide) has been approved. Patent protections have kept competitors out. The earliest estimated date for generic entry is mid-2026, which could eventually improve availability and bring prices down — but that relief hasn't arrived yet.
When you have a single manufacturer serving the entire market for a medication, any disruption — a production delay, a raw material shortage, a distribution hiccup — can ripple across the country. Brand-only drugs like Aplenzin are inherently more vulnerable to these issues.
Cost is a major factor in the Aplenzin story. Here's what patients are facing:
For detailed strategies on reducing your costs, see how to save money on Aplenzin XR in 2026.
A few developments may help Aplenzin patients this year:
Patent analysis suggests the earliest date for a generic Bupropion Hydrobromide product could be June 2026. If a generic launches, it could dramatically lower costs and increase availability. We'll update this post as new information becomes available.
Bausch Health continues to offer the Aplenzin Savings & Access Program, which includes copay savings for commercially insured patients and may provide free delivery. The Bausch Health Patient Assistance Program (bauschhealthpap.com) offers free medication to qualifying uninsured or underinsured patients.
If you need a new prescription or need to discuss alternatives, telehealth psychiatry and primary care appointments can save you time. Many telehealth providers can prescribe Aplenzin or help you switch formulations. See our guide on finding a doctor who can prescribe Aplenzin XR.
Here's your action plan:
For a complete strategy guide, read how to find Aplenzin XR in stock near you.
The Aplenzin XR situation in 2026 is a combination of limited supply, high cost, and systemic insurance barriers — not a traditional manufacturing shortage. But for patients who rely on this medication, the distinction doesn't matter much when your pharmacy says "we don't have it."
Stay proactive: use Medfinder to track availability, keep your prescriber informed, explore savings programs, and know your alternatives. The landscape may improve later in 2026 if generic options arrive, but for now, preparation is your best tool.
For a comprehensive look at what to expect from this medication, visit our guide on what Aplenzin XR is, its uses, and what you need to know.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.